Last reviewed · How we verify

Cetuximab, irinotecan

Asan Medical Center · Phase 2 active Small molecule

Cetuximab, irinotecan is a Small molecule drug developed by Asan Medical Center. It is currently in Phase 2 development. Also known as: PharmDx kit for EGFR staining..

At a glance

Generic nameCetuximab, irinotecan
Also known asPharmDx kit for EGFR staining.
SponsorAsan Medical Center
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Cetuximab, irinotecan

What is Cetuximab, irinotecan?

Cetuximab, irinotecan is a Small molecule drug developed by Asan Medical Center.

Who makes Cetuximab, irinotecan?

Cetuximab, irinotecan is developed by Asan Medical Center (see full Asan Medical Center pipeline at /company/asan-medical-center).

Is Cetuximab, irinotecan also known as anything else?

Cetuximab, irinotecan is also known as PharmDx kit for EGFR staining..

What development phase is Cetuximab, irinotecan in?

Cetuximab, irinotecan is in Phase 2.

Related